- In April 2024, Eli Lilly and Company received expanded FDA approval for its dual GIP/GLP-1 receptor agonist, tirzepatide (marketed as Mounjaro), for chronic weight management in individuals without type 2 diabetes. This landmark approval significantly broadens the therapeutic scope of the drug, reinforcing Lilly’s leadership position in the metabolic disease treatment space and accelerating its global commercialization strategy for dual agonists
- In March 2024, Novo Nordisk A/S announced the initiation of a global Phase 3 trial for its next-generation dual GIP/GLP-1 receptor agonist targeting obesity and cardiovascular risk reduction. This pipeline advancement follows the success of semaglutide and aligns with the company’s ambition to address unmet needs in obesity and cardiometabolic care through innovative incretin-based therapies
- In February 2024, Amgen Inc. disclosed positive interim results from its Phase 2 study of AMG 133, a novel GIPR/GLP-1R dual agonist. The trial demonstrated substantial weight loss and improved glycemic control, with a favorable safety profile. The development positions Amgen as a strong emerging competitor in the dual agonist obesity treatment landscape
- In January 2024, Structure Therapeutics entered a strategic partnership with Huadong Medicine Co., Ltd. to co-develop and commercialize oral GIP/GLP-1 receptor agonists in the Asia-Pacific region. This collaboration aims to accelerate the development of orally administered therapies, addressing the growing demand for convenient, non-injectable solutions in obesity management
- In December 2023, Zealand Pharma announced the successful completion of preclinical studies for its investigational triple agonist (GLP-1, GIP, and glucagon receptor), demonstrating superior weight loss and metabolic effects compared to dual agonists. The company plans to initiate human trials in 2025, signaling a shift toward multi-targeted peptide therapeutics in the obesity space
